Citadel Advisors
ONCY

Citadel Advisors’s Oncolytics Biotech ONCY Stock Holding History

Citadel Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.2K Buy
+17,938
New +$17.8K ﹤0.01% 12714
2025
Q4 		– Sell
-382,051
Closed -$535K – 13678
2025
Q3 		$535K Buy
+382,051
New +$428K ﹤0.01% 8963
2024
Q4 		– Sell
-79,249
Closed -$69K – 15127
2024
Q3 		$69K Sell
79,249
-57,836
-42% -$56.8K ﹤0.01% 11578
2024
Q2 		$136K Sell
137,085
-25,680
-16% -$28K ﹤0.01% 10490
2024
Q1 		$173K Buy
162,765
+48,880
+43% +$54.6K ﹤0.01% 10553
2023
Q4 		$154K Buy
+113,885
New +$178K ﹤0.01% 10343
2023
Q2 		– Sell
-87,858
Closed -$105K – 14972
2023
Q1 		$105K Buy
87,858
+50,587
+136% +$79.4K ﹤0.01% 11185
2022
Q4 		$60.8K Buy
+37,271
New +$56.6K ﹤0.01% 11899
2022
Q2 		– Sell
-11,639
Closed -$18K – 13744
2022
Q1 		$18K Sell
11,639
-83,696
-88% -$140K ﹤0.01% 13275
2021
Q4 		$133K Buy
95,335
+78,347
+461% +$145K ﹤0.01% 12415
2021
Q3 		$36K Sell
16,988
-12,401
-42% -$28.1K ﹤0.01% 13511
2021
Q2 		$81K Sell
29,389
-19,989
-40% -$61.2K ﹤0.01% 13070
2021
Q1 		$188K Buy
+49,378
New +$147K ﹤0.01% 11778
2020
Q4 		– Sell
-23,139
Closed -$39K – 11350
2020
Q3 		$39K Sell
23,139
-14,897
-39% -$27.3K ﹤0.01% 9681
2020
Q2 		$72K Buy
+38,036
New +$71.6K ﹤0.01% 9143
2020
Q1 		– Sell
-32,465
Closed -$154K – 9997
2019
Q4 		$154K Buy
32,465
+15,549
+92% +$17.6K ﹤0.01% 8348
2019
Q3 		$10K Buy
+16,916
New +$17.2K ﹤0.01% 9040
2019
Q2 		– Sell
-29,520
Closed -$54K – 9661
2019
Q1 		$54K Buy
+29,520
New +$59.8K ﹤0.01% 8791

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors's ONCY Position: Q1 2026 in Review

Citadel Advisors opened a new position in Oncolytics Biotech (ONCY) in Q1 2026: 17,938 shares worth $15.2K. The stake represents ﹤0.01% of the portfolio and ranks #12714 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ONCY as recently as Q3 2025.

Citadel Advisors first reported a position in ONCY in Q1 2019 and has held it in 18 quarters since. The position peaked at $535K in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Citadel Advisors held 17,938 shares of Oncolytics Biotech worth $15.2K as of Q1 2026.
  • Oncolytics Biotech was a new Citadel Advisors position in Q1 2026.
  • Oncolytics Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12714 holding.
  • Citadel Advisors first reported a position in Oncolytics Biotech in Q1 2019 and has held it in 18 quarters since.
  • Citadel Advisors's Oncolytics Biotech position peaked at $535K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.